Cargando…

Uveitis outcome and complication

Detalles Bibliográficos
Autor principal:	Foeldvari, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184121/ http://dx.doi.org/10.1186/1546-0096-12-S1-I5

Ejemplares similares

Uveitis: basic concepts and differential diagnosis
por: Edelsten, Clive
Publicado: (2014)

PReS13-SPK-1247: Activity and damage in juvenile systemic sclerosis- we have to measure them
por: Foeldvari, I
Publicado: (2013)

Systematic review on treatment of juvenile idiopathic arthritis – associated uveitis
por: Heiligenhaus, Arnd
Publicado: (2014)

Treatment of gastrointestinal complication in transthyretin amyloidosis. A single centre’s experience
por: Suhr, Ole B
Publicado: (2015)

The clinical picture and outcome in adults
por: Elewaut, Dirk
Publicado: (2014)

Statistical validation of surrogate outcome measures
por: Buyse, Marc
Publicado: (2011)

Patient reported outcomes: past, present, and future
por: Scott, Jane A
Publicado: (2011)

INSP-07. Improving cognitive outcomes for children treated for cancer: moving beyond the cure
por: Conklin, Heather
Publicado: (2022)

Hydrocephalus treatment and outcome in African infants with myelomeningocele: what we have learned so far
por: Warf, Benjamin C
Publicado: (2010)

Adaptation of forest trees to climate change
por: Plomion, Christophe, et al.
Publicado: (2011)

INSP-06. Recent advances in improving neuropsychological outcomes for paediatric brain tumour patients - Are we entering a new era?
por: Mabbott, Donald
Publicado: (2022)

INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
por: Jonchere, Barbara, et al.
Publicado: (2022)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

INSP-08. Cerebellar mutism syndrome: incidence, symptoms, risk factors, prognosis. Results and future perspectives from the Nordic-European study of the cerebellar mutism syndrome
por: Sehested, Astrid, et al.
Publicado: (2022)

INSP-03. Neuronal regulation of glioma progression
por: Monje, Michelle
Publicado: (2022)

INSP-17. Augmented Drug Delivery for Pediatric Diffuse Midline Glioma using Convection Enhanced Delivery
por: Souweidane, Mark M
Publicado: (2022)

INSP-14. Novel approaches to molecular diagnostics
por: Sahm, Felix
Publicado: (2022)

INSP-01. What to do when you cannot randomize? Leveraging Historical Data in Efficient Study Designs for Pediatric Neuro-Oncology.
por: Onar-Thomas, Arzu
Publicado: (2022)

INSP-02. WHO 2021 classification of CNS tumors
por: Wesseling, Pieter
Publicado: (2022)

INSP-16. Focused ultrasound-mediated blood-brain barrier disruption for the treatment of pediatric high-grade glioma
por: van Vuurden, Dannis, et al.
Publicado: (2022)

INSP-05. Development of fast cortical rhythms in health and mental disease
por: Hanganu-Opatz, Ileana
Publicado: (2022)

S7. KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells
por: Maccalli, C, et al.
Publicado: (2014)

S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
por: Liu, Z, et al.
Publicado: (2014)

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4
por: Sharma, P
Publicado: (2014)

S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing
por: Reuther, S, et al.
Publicado: (2014)

S79. CAR strategies in solid tumours
por: Rossig, C
Publicado: (2014)

S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial
por: Schmoll, H, et al.
Publicado: (2014)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

S50. Proffered paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics
por: Layman, H, et al.
Publicado: (2014)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
por: Grassmann, S, et al.
Publicado: (2014)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment
por: Gajewski, T
Publicado: (2014)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology
por: Jahn, L, et al.
Publicado: (2014)

S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Cojocaru, G, et al.
Publicado: (2014)

S47. Tumour infiltrating lymphocytes - a predictive marker?
por: Galon, J
Publicado: (2014)

S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response
por: Dalgleish, A, et al.
Publicado: (2014)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_frskbji64nkv9evfi0a93vms07